CAPOZIDE 50/15 Drug Patent Profile
Which patents cover Capozide 50/15, and when can generic versions of Capozide 50/15 launch?
Capozide 50/15 is a drug marketed by Apothecon and is included in one NDA.
The generic ingredient in CAPOZIDE 50/15 is captopril; hydrochlorothiazide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the captopril; hydrochlorothiazide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Capozide 50/15
A generic version of CAPOZIDE 50/15 was approved as captopril; hydrochlorothiazide by RISING on December 29th, 1997.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CAPOZIDE 50/15?
- What are the global sales for CAPOZIDE 50/15?
- What is Average Wholesale Price for CAPOZIDE 50/15?
Summary for CAPOZIDE 50/15
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 8 |
| Clinical Trials: | 1 |
| Patent Applications: | 656 |
| DailyMed Link: | CAPOZIDE 50/15 at DailyMed |
Recent Clinical Trials for CAPOZIDE 50/15
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| GlaxoSmithKline | Phase 1 |
US Patents and Regulatory Information for CAPOZIDE 50/15
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apothecon | CAPOZIDE 50/15 | captopril; hydrochlorothiazide | TABLET;ORAL | 018709-004 | Oct 12, 1984 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CAPOZIDE 50/15
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Apothecon | CAPOZIDE 50/15 | captopril; hydrochlorothiazide | TABLET;ORAL | 018709-004 | Oct 12, 1984 | 4,105,776 | ⤷ Start Trial |
| Apothecon | CAPOZIDE 50/15 | captopril; hydrochlorothiazide | TABLET;ORAL | 018709-004 | Oct 12, 1984 | 4,217,347 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CAPOZIDE 50/15
See the table below for patents covering CAPOZIDE 50/15 around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Argentina | 213102 | PROCEDIMIENTO PARA OBTENER COMPUESTOS DE ESPIRO(1,3-DIOXALAN-4,3')QUINUCLIDINA Y SUS SALES | ⤷ Start Trial |
| Argentina | 213184 | PROCEDIMIENTO PARA PREPARAR DERIVADOS DE 1,4-ETAN-6-OXO-PERHIDROQUINOLEINA Y SUS SALES | ⤷ Start Trial |
| Argentina | 214649 | PROCEDIMIENTO PARA PREPARAR NUEVOS ACIDOS Y ESTERES DE ALQUILO DE 1-(3-MERCAPTOPROPANOIL O 3-MERCAPTO-2-ALQUIL(C1-C7)-PROPANOIL)-L-PROLINA | ⤷ Start Trial |
| Argentina | 214652 | PROCEDIMIENTO PARA OBTENER COMPUESTOS DE ESPIRO(1,3-DIOXOLAN-4,3')QUINUCLIDINA Y SUS SALES | ⤷ Start Trial |
| Argentina | 222445 | PROCEDIMIENTO PARA PREPARAR NUEVOS DERIVADOS DE ACIDO 1-(MERCAPTOALQUIL-(C1-C3)-CARBONIL)-L-PROLINA Y SUS SALES | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch